drugset / Trial / NCT00456521

A Safety and Efficacy Study of Naltrexone SR/Bupropion SR and Placebo in Overweight and Obese Subjects Participating in an Intensive Behavior Modification Program

NCT00456521

Phase 3 Completed 793 enrolled Orexigen Therapeutics, Inc
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to determine whether a combination of naltrexone SR and bupropion SR is safe and effective in treating obesity and leads to greater weight loss when given with a group lifestyle modification program than with group lifestyle modification alone.

Timeline

Start
2007-03
Primary completion
2008-12
Completion
2008-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Bupropion Small molecule 360 mg
Subject Naltrexone Small molecule 32 mg

Indications